Chemomab Therapeutics (CCMB) investor relations material

Key presentations and announcements

• Presented positive phase II results for Nebucadnezar in primary sclerosing cholangitis (PSC), showing proof of concept and significant anti-inflammatory and anti-fibrotic activity.

• Identified 20 mg/kg as the optimal dose and moderate to advanced PSC patients as the target population for phase III.

• Reported high patient compliance and sustained biomarker improvements over 48 weeks in the open-label extension.

• Achieved 80% reduction in clinical events compared to historical controls after one year of treatment.

• Announced FDA alignment on a single pivotal phase III study for full approval, with plans to initiate soon and ongoing partnership discussions.

Industry and market analysis

• PSC represents a rare disease with no approved therapies and a significant unmet need, affecting about 70,000 patients in major markets.

• Nebucadnezar is positioned as a potential first-in-class, disease-modifying therapy with limited competition.

• Projected annual commercial opportunity exceeds $1 billion, supported by premium pricing expectations.

• Strong investor backing and strategic partner interest driven by robust clinical data.

• The drug's dual mechanism may have applications in other fibrotic diseases beyond PSC.

Forward-looking statements and plans

• Preparing to launch a pivotal phase III trial in PSC, focusing on clinical event endpoints for regulatory approval.

• Aiming to secure a partner to accelerate phase III initiation and potential market entry.

• Ongoing evaluation of Nebucadnezar in other fibrotic indications, including systemic sclerosis and IPF.

• Emphasizing the transformative impact of positive phase II results for both the company and the PSC field.

• Highlighting continued engagement with the FDA and partners to expedite development.